SuperworthMimedx EPS MDXG
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $0.04
- Latest quarter, Q2 FY26
- −$0.10
- −267% on a year earlier
- Fiscal year 2025
- $0.32
- +14% on the year before
Mimedx's earnings per share was $0.04 over the twelve months to Jun 30, 2026, down 81% on a year earlier.
In its latest quarter, Q2 FY26, it was −$0.10, down 267% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.32 | +14% |
| FY2024 | $0.28 | +17% |
| FY2023 | $0.24 | n/a |
| FY2022 | −$0.33 | n/a |
| FY2021 | −$0.15 | n/a |
| FY2020 | −$0.77 | n/a |
| FY2019 | −$0.24 | n/a |
| FY2018 | −$0.28 | −355% |
| FY2016 | $0.11 | −58% |
| FY2015 | $0.26 | +420% |
| FY2014 | $0.05 | n/a |
| FY2013 | −$0.04 | n/a |
| FY2012 | −$0.09 | n/a |
| FY2011 | −$0.14 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.10 | −267% | $0.04 | |
| Q1 FY26 | −$0.07 | −240% | $0.20 | |
| Q4 FY25 | $0.10 | +100% | $0.32 | |
| Q3 FY25 | $0.11 | +120% | $0.27 | |
| Q2 FY25 | $0.06 | −50% | $0.21 | |
| Q1 FY25 | $0.05 | −17% | $0.27 | |
| Q4 FY24 | $0.05 | −78% | $0.28 | |
| Q3 FY24 | $0.05 | −17% | $0.46 | |
| Q2 FY24 | $0.12 | +1100% | $0.47 | |
| Q1 FY24 | $0.06 | n/a | $0.36 | |
| Q4 FY23 | $0.23 | n/a | $0.24 | |
| Q3 FY23 | $0.06 | n/a | −$0.01 |
Against its peers
Companies in Medical - Instruments & Supplies nearest Mimedx's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| MDXGMimedx | $0.04 | −81% a year |
| TCMDTactile Systems Technology | $1.08 | +74% a year |
| MOVMovado | $1.80 | +137% a year |
| EMBCEmbecta | $1.47 | +3% a year |
| IRMDIradimed | $1.79 | +10% a year |
| STAAStaar Surgical | $0.07 | |
| INFUInfuSystem | $0.41 | +78% a year |
| BVSBioventus | $0.77 | |
| CDRECadre | $0.81 | −14% a year |
| UTMDUtah Medical Products | $3.28 | −12% a year |
| EYENational Vision | $0.61 | |
| Peer median | $0.94 |
Where Mimedx ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Mimedx
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.